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Managing non-alcoholic fatty liver disease in
diabetes: Challenges and opportunities
Non-alcoholic fatty liver disease (NAFLD) and type 2 dia-
betes mellitus are two common health problems worldwide.
Globally, it has been estimated that one-quarter of the adult
population in the world currently suffers from NAFLD1. In
Asia, probably attributed to the obesity epidemic, the preva-
lence of NAFLD was similar, or even slightly higher, when
compared with that in the Western population (27% in Asia
vs 24.1% in North America and 23.7% in Europe), and the
incidence was approximately 52 per 1,000 person-years1. Sim-
ilarly, there are more than 380 million people with diabetes
worldwide, and the International Diabetes Federation esti-
mates that this will rise to almost 592 million within a gen-
eration. Importantly, individuals with NAFLD are often
comorbid with type 2 diabetes, or vice versa. Type 2 diabetes
is present in almost one-quarter of patients with NAFLD
and in almost half of those with non-alcoholic steatohepatitis
(NASH), a critical stage in the spectrum of NAFLD. In con-
trast, NAFLD is found in as many as 75% of patients with
type 2 diabetes.1 Strikingly, these two conditions can interact
with each other and cause a signiﬁcant negative health
impact. The presence of NAFLD increases the risk of all-
cause mortality among patients with type 2 diabetes, whereas
type 2 diabetes increases the risk of advanced ﬁbrosis by
threefold, doubles the risk of hepatocellular carcinoma, and
independently predicts the overall and liver mortality in
NAFLD. However, given the large scale of the problem and
the projected considerable healthcare burden, multiple limita-
tions and unmet needs in the management of NAFLD in
type 2 diabetes patients remain to be addressed.
First, despite this strong and proven bidirectional relation-
ship between NAFLD and type 2 diabetes, speciﬁc guidelines
are still lacking on whom, when and how to screen for
NAFLD among patients with type 2 diabetes. Universal
screening for NAFLD in type 2 diabetes patients is not
advocated in the current practice guidelines for NAFLD man-
agement in the USA, partly related to the issue of cost-effec-
tiveness. NAFLD is deﬁned as the presence of more than 5%
of hepatic steatosis. Commonly used imaging techniques, such
as hepatic ultrasound, are insensitive to mild hepatic steatosis
(<30%). In contrast, more sensitive tools, such as magnetic
resonance spectroscopy, are however, limited by cost and
availability. In addition, as NAFLD spans a spectrum from
simple hepatic steatosis to NASH, liver cirrhosis and hepato-
cellular carcinoma, universal screening for NAFLD in type 2
diabetes patients could result in the inclusion of a proportion
of patients who might remain as simple hepatic steatosis with
minimal risk of progression.
Second, although type 2 diabetes is well known to be a
risk factor for NAFLD progression, monitoring of disease
progression is challenging. Measuring alanine aminotransferase
(ALT) levels is an insensitive method of disease monitoring,
as ALT ﬂuctuates within the spectrum of NAFLD1. Liver
biopsy used to be the gold standard for evaluating the differ-
ent stages of NAFLD. However, this is limited by its invasive
nature, sampling errors and complication rates. Indeed, given
the large number of type 2 diabetes patients suffering from
NAFLD, it is both impractical and technically difﬁcult to fol-
low them up individually for their hepatic progression using
serial liver biopsies. The advent of transient elastography has
rendered a non-invasive monitoring of both hepatic steatosis
and ﬁbrosis feasible, while utilizing estimates from the con-
trolled attenuation parameter and liver stiffness measurements,
respectively. Currently, however, it is still not possible to dif-
ferentiate NASH from simple hepatic steatosis using non-
invasive and commercially available tools, including transient
elastography.
Over the years, there has been extensive research looking for
sensitive and well-validated biomarkers for NASH. Some are
quite promising, such as circulating cytokeratin-18 fragment, a
hepatocyte apoptotic marker, as well as several adipokines or
obesity-related protein markers that have also been investigated
as emerging NASH biomarkers, partly because obesity serves as
a common risk factor for NAFLD and type 2 diabetes2. Our
observation of a protective role of adiponectin in NASH, pub-
lished in the Journal of Clinical Investigation in 20033 has been
extensively replicated. We also found, in a study published in
Journal of Hepatology in 20134, that the expression of adipocyte
fatty acid-binding protein, an adipokine involved in the trafﬁck-
ing of lipids, was elevated in the Kupffer cells of mice with
NASH, and treatment with a small molecule of adipocyte fatty
acid-binding protein inhibitor could protect obese mice from
NASH. In addition, along with our Australian collaborators, we
found that circulating adipocyte fatty acid-binding protein levels
positively correlated with the degree of inﬂammation and ﬁbro-
sis in NAFLD. In humans, serum levels of ﬁbroblast growth
factor 21 (FGF21), an emerging metabolic regulator closely
related to various obesity-related conditions, were elevated in
patients with biopsy-proven NASH compared with that of
healthy controls. Whether these circulating proteins could be
usefully employed as NASH biomarkers, especially in type 2
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diabetes patients, remains to be conﬁrmed in large diabetic
cohorts. Nevertheless, these ﬁndings have opened up opportuni-
ties for better understanding of the complex pathogenic mecha-
nisms of NASH, which undoubtedly, has become a major
complication of type 2 diabetes.
Finally, managing NAFLD in type 2 diabetes is further chal-
lenged by the limitation of treatment strategies. To our knowl-
edge, other than lifestyle modiﬁcation, there is currently no
licensed or approved pharmacological therapy for the treatment
of NAFLD. Lifestyle modiﬁcation is easier said than done.
Patients who have initiated lifestyle intervention with dietary
modiﬁcation and weight reduction often have difﬁculties in
maintaining their efforts. In recent years, however, new agents
for the management of NAFLD in type 2 diabetes have
emerged (Figure 1). Farnesoid X nuclear receptor agonist, for
instance, is a novel class of agents that was shown in a multi-
center, randomized, placebo-controlled trial published in 2015
to show beneﬁts in patients with type 2 diabetes and NASH.
Activation of farnesoid X nuclear receptor inhibits hepatic de
novo lipogenesis, hepatic gluconeogenesis and glycogenolysis5.
In the farnesoid X nuclear receptor ligand obeticholic acid for
non-cirrhotic, non-alcoholic steatohepatitis trial, which com-
prised more than 50% of participants with type 2 diabetes (142
out of 283 participants), obeticholic acid improved the histolog-
ical features of NASH after 72 weeks of treatment.
Although the long-term efﬁcacy and safety data of farnesoid
X nuclear receptor agonists are eagerly awaited, the presence of
NAFLD in patients with type 2 diabetes might well inﬂuence
the choice of antidiabetic agents. Indeed, there are emerging
data of NAFLD protection among various existing agents in
the growing list of antidiabetic armamentarium. (Figure 1)
Pioglitazone, the only thiazolidinedione currently available on
the market, was shown in a proof-of-concept study published
by Beifort et al. in the New England Journal of Medicine in
20066 to improve steatosis, ballooning and inﬂammation
among patients with impaired glucose tolerance or type 2 dia-
betes. Thiazolidinediones are peroxisome proliferator activated
receptor gamma agonists that possess potent insulin-sensitizing
properties. They mediate NAFLD protection through increasing
adiponectin levels, resulting in a reduction in free fatty acid
inﬂux, increased fatty acid oxidation and decreased inﬂamma-
tion. In contrast, the incretin-based therapies, which comprise
oral dipeptidyl peptidase-4 inhibitors and injectable glucagon-
like peptide-1 (GLP1) receptor agonists, have also been sug-
gested as effective treatment options of NAFLD in a recent
meta-analysis7. However, the primary outcome used was solely
the reduction in serum ALT levels, and among the incretin-
based therapies, only sitagliptin and liraglutide have been exten-
sively studied in humans. Nevertheless, as dipeptidyl peptidase-
4 expression is found in hepatic stellate cells, it has been
postulated that dipeptidyl peptidase-4 inhibitors might attenuate
the activation of hepatic stellate cells, and decrease the produc-
tion of hepatic transforming growth factor-beta 1. With regard
to GLP1 receptor agonists, although the presence of GLP1
receptors on human hepatocytes remains controversial, it is
possible that GLP1 receptor agonists can mediate NAFLD pro-
tection through mechanisms other than an improvement in
glycemic control and considerable weight loss. In animal stud-
ies, liraglutide has been shown to increase FGF21, FGF receptor
messenger ribonucleic acid and protein expression. In fact, in
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Figure 1 | Potentially useful pharmacotherapy for management of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes. DPP4i,
dipeptidyl peptidase-4 inhibitors; FXRa, farnesoid X receptor agonists; GLP1Ra, glucagon-like peptide receptor agonists; NASH, non-alcoholic
steatohepatitis; SGLT2i, sodium–glucose cotransporter 2 inhibitors.
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diet-induced obese mice, chronic treatment with recombinant
FGF21 also improved hepatic steatosis through the inhibition
of hepatic lipogenesis2, although the use of recombinant FGF21
analogs to treat NAFLD in human subjects with type 2 diabetes
remains to be investigated2. More recently, the sodium–glucose
cotransporter 2 inhibitors, the ﬁrst oral hypoglycemic agent to
show cardiovascular beneﬁts, have been shown to be another
antidiabetic drug that can be of beneﬁt in NAFLD. Sodium–
glucose cotransporter 2 inhibitors improved hepatic steatosis in
mice models, through a decrease in de novo lipogenesis and
possibly an increase in fatty acid oxidation8. Furthermore, the
use of ipragliﬂozin also improved liver dysfunction in terms of
ALT levels, independent of weight changes, among 25 subjects
with coexisting type 2 diabetes and ultrasound-proven hepatic
steatosis8.
Opportunities follow challenges. This has been well demon-
strated over the past decade in the management of NAFLD in
type 2 diabetes patients. Clearly, there exists a gap between sci-
entiﬁc evidence and current clinical practice, as well as multiple
unmet needs, from diagnostics to therapeutics. Nevertheless, we
can foresee that the tremendous efforts of both clinicians and
scientists, striving to turn such challenges into opportunities of
medical advancement, will bring in new insights and break-
throughs, to overcome this emerging complication of diabetes.
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